ERFSF Stock Recent News

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM   1. Details of the person discharg.

Eurofins Scientific SE (OTCPK:ERFSF) Q2 2025 Earnings Conference Call April 23, 2025 9:00 AM ET Company Participants Gilles Martin - Chairman and CEO Laurent Lebras - Group Administration and CFO Conference Call Participants Remi Grenu - Morgan Stanley Suhasini Varanasi - Goldman Sachs Delphine Le Louet - Bernstein Neil Tyler - Redburn Atlantic Arthur Truslove - Citi Allen Wells - Jefferies Pablo Cuadrado - Kepler Unidentified Company Representative Ladies and gentlemen, welcome and thank you for joining Eurofins' Q1 2025 Trading Update Presentation. Please note that this call is being recorded and will later be available for replay on the Eurofins Investor Relations' website.

Here is how EUROFINS SCIENT (ERFSF) and Genelux Corporation (GNLX) have performed compared to their sector so far this year.

EUROFINS SCIENT (ERFSF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how EUROFINS SCIENT (ERFSF) and Abbott (ABT) have performed compared to their sector so far this year.

Eurofins Scientific SE (OTCPK:ERFSF) Q4 2024 Earnings Call Transcript January 30, 2025 9:00 AM ET Company Participants Gilles Martin - Chairman of the Board & Chief Executive Officer Laurent Lebras - Group Administration and Chief Financial Officer Conference Call Participants Annelies Vermeulen - Morgan Stanley Suhasini Varanasi - Goldman Sachs Pablo Cuadrado - Kepler Cheuvreux James Clark - Barclays Himanshu Agarwal - Bank of America Allen Wells - Jefferies Arthur Truslove - Citi Operator Ladies and gentlemen, welcome, and thank you for joining Eurofins' FY 2024 Results Presentation. Please note that this call is being recorded and will later be available for replay on the Eurofins Investor Relations website.

Eurofins Scientific's EBITDA fell post COVID, but growth is expected to resume with aggressive targets, making the stock appealing despite recent setbacks. The company confirmed its 2024 outlook, expecting close to 7B EUR in revenue and adjusted EBITDA of 1.53-1.58B EUR, with higher margins. Eurofins plans to double net free cash flow by 2027 through M&A, with a comfortable leverage ratio allowing for more acquisitions.

Eurofins Scientific faced a short attack by Muddy Waters but has since recovered, maintaining strong financials and cash flow despite the initial share price drop. The company reported a net profit of 220.7M EUR and an attributable net free cash flow of 217M EUR in H1, supporting its financial health. Eurofins aims for 1.55B EUR in EBITDA for 2024 and 2.4B EUR by 2027, showing confidence in its long-term growth strategy.

EUROFINS SCIENT (ERFSF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Eurofins Scientific SE (OTCPK:ERFSF) Q2 2024 Earnings Call July 24, 2024 9:00 AM ET Company Participants Gilles Martin - Chief Executive Officer Laurent Lebras - Chief Financial Officer Conference Call Participants Suhasini Varanasi - Goldman Sachs Himanshu Agarwal - Bank of America Neil Tyler - Redburn Atlantic Arthur Truslove - Citi James Rose - Barclays Allen Wells - Jefferies Delphine Le Louet - Bernstein Operator Ladies and gentlemen, welcome and thank you for joining Eurofins Half Year 2024 Results Call. Please note that this call is being recorded and will later be available for replay on the Eurofins Investor Relations website.